» Articles » PMID: 1835963

Lack of Pharmacokinetic Interaction As an Equivalence Problem

Overview
Specialty Pharmacology
Date 1991 Aug 1
PMID 1835963
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

The demonstration that concomitant administration of drug B does not affect the pharmacokinetics of drug A can be adequately handled as an equivalence problem. Administration of drug A alone serves as reference and simultaneous administration of drugs A and B as test situation. The range of clinically acceptable variation in the pharmacokinetic characteristics of drug A defines the equivalence range. This will usually correspond to the bioequivalence range accepted for the comparison of different formulations of drug A. Equivalence, i.e. lack of pharmacokinetic interaction, is concluded if the 90%-confidence interval for the ratio (difference) of the expected medians for test and reference is entirely within the equivalence range. This decision procedure ensures that the consumer risk of incorrectly concluding "lack of interaction" is limited to 5%. Moreover, the producer risk of incorrectly concluding "interaction" can be controlled by appropriate sample sizes.

Citing Articles

Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Tothfalusi L, Endrenyi L, Garcia Arieta A Clin Pharmacokinet. 2009; 48(11):725-43.

PMID: 19817502 DOI: 10.2165/11318040-000000000-00000.


What is the true risk of a pharmacokinetic drug-drug interaction?.

Fuhr U Eur J Clin Pharmacol. 2007; 63(10):897-9.

PMID: 17684737 DOI: 10.1007/s00228-007-0357-6.


Effect of gemfibrozil on the pharmacokinetics of pioglitazone.

Deng L, Wang F, Li H Eur J Clin Pharmacol. 2005; 61(11):831-6.

PMID: 16283275 DOI: 10.1007/s00228-005-0042-6.


Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.

Depre M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P Eur J Clin Pharmacol. 2005; 61(5-6):341-6.

PMID: 15983826 DOI: 10.1007/s00228-005-0907-8.


Induction of the metabolism of etizolam by carbamazepine in humans.

Kondo S, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Inoue Y Eur J Clin Pharmacol. 2005; 61(3):185-8.

PMID: 15776275 DOI: 10.1007/s00228-005-0904-y.